Delivery Order SPE2DR25D1103-SPE2DR26FE623
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Jardiance 10 mg tablets (90-count packages) with a contract ceiling value of $11,562.78. This is a firm fixed-price delivery order with an ultimate completion date of January 6, 2026, utilizing no set-aside designation and awarded through competitive procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, non-set-aside contract is valued at $1,807.80 and utilizes firm fixed price terms. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate office and primary distribution...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Jardiance 10 mg tablets (90-count units) with a ceiling value of $3,462.82. This is a firm fixed price delivery order with an ultimate completion date of June 9, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Jardiance 10 mg tablets (90-count packages) under a firm fixed-price contract valued at $22,046.39, with completion scheduled for January 6, 2026. This non-set-aside award represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order contract valued at $10,709.98 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count packages). This firm fixed-price delivery order, awarded on December 8, 2025, with an ultimate completion date of December 9, 2025, represents a competitively awarded non-set-aside contract. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Jardiance 10 mg tablets in a 90-count package. This is a firm fixed-price delivery order with a ceiling value of $12,387.85 and an ultimate completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and was awarded without a set-aside designation, indicating it was competed among...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Jardiance 25 mg tablets (90-count packages) valued at $23,033.06. This firm fixed-price delivery order, with an ultimate completion date of October 23, 2025, was competitively awarded with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, leveraging the company's extensive pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 19, 2025, for the supply of Jardiance 10 mg tablets (90-count) with a ceiling value of $8,006.67. This is a firm fixed price delivery order with an ultimate completion date of December 22, 2025, and no set-aside designation was used. The contract represents a competitive award for pharmaceutical procurement supporting federal medical supply needs, with performance taking place at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,648.51 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units). This firm fixed-price, competitively awarded contract was executed on December 29, 2025, with an ultimate completion date of December 30, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,966.34 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count packages) on January 5, 2026, with completion scheduled for January 6, 2026. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FE623Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Jardiance 10 mg tablets in a quantity of 90 units, with a ceiling value of $2,406.07. This is a firm fixed price delivery order with an ultimate completion date of January 6, 2026, issued under a non-competitive set-aside arrangement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at approximately $1 billion through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support federal military and veteran healthcare systems. The Jardiance delivery represents a routine pharmaceutical procurement for military medical supply chain operations, consistent with the company's ongoing role as a critical vendor for brand-name and generic medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 1/4/26 |